1. Market Performance A - Share Market - The Shanghai Composite Index rose 0.43% to 3361.98 points, the Shenzhen Component Index rose 0.16%, and the Chi - Next Index rose 0.48%. Jewelry and jewelry maintained their strength, while the overall performance of the automobile manufacturing industry was mediocre, showing a divergence from the Hong Kong stock market [1]. Hong Kong Stock Market - The Hang Seng Index closed up 1.53% at 23512.49 points, the Hang Seng Tech Index rose 1.08%, and the Hang Seng China Enterprises Index rose 1.92%. Automobile and bank stocks led the rebound, with a total market turnover of HK$203.681 billion [1]. Overseas Markets - European stock markets closed higher. In the US, the Dow Jones Industrial Average rose 0.51%, the S&P 500 Index rose 0.58% to 5970.37 points, and the Nasdaq Composite Index rose 0.81% [1]. 2. Macroeconomic News US Labor Market - In April, US job openings unexpectedly increased significantly, with recruitment activities accelerating, indicating a still - robust labor demand. Job openings rose from a revised 7.2 million in March to 7.39 million, higher than the expected median of 7.1 million. The increase was mainly in the private sector, such as professional and business services, and healthcare and social assistance. Although there were fewer openings in state and local education, federal government job openings increased. However, economists expect the labor market to weaken more significantly in the coming months under the impact of Trump's tariff policies [12]. US Steel and Aluminum Tariffs - US President Donald Trump signed an order on Tuesday to raise steel and aluminum tariffs from 25% to 50% starting from June 4, aiming to help domestic manufacturers. The tariff on steel and aluminum imported from the UK will remain at 25%. This move intensifies trade tensions [8][12]. South Korean Presidential Election - South Korean opposition candidate Lee Jae - myung won the presidential election, with about 48.8% of the votes, while ruling - party candidate Kim Min - soo got 42.0%. This election is seen as a referendum on the failure of former President Yoon Suk - yeol's martial - law order. Lee Jae - myung faces challenges in uniting the divided country and restoring economic growth [12]. 3. Corporate News IPO News - Yisw Compute, a leading RISC - V chip company, submitted a prospectus to the Hong Kong Stock Exchange on May 30. It has completed four rounds of financing in five years, with a total scale of over RMB 9 billion. Its listing is expected to inject new impetus into China's semiconductor industry [10]. Corporate Actions - China Ping An plans to issue zero - coupon convertible bonds worth HK$1.1765 billion, maturing in 2030, with an initial conversion price of HK$55.02 per H - share [14]. - Midea Group has repurchased about 12.1888 million A - shares for about RMB 899 million as of May 31 [14]. - CITIC Bank has been approved to establish CITIC Financial Asset Investment, with a proposed registered capital of RMB 10 billion [14]. - COSCO SHIPPING Holdings has cancelled about 144 million repurchased shares, and its controlling shareholder's shareholding has increased to over 45% [14]. - Haier Smart Home repurchased about 6.3642 million A - shares in May for about RMB 164 million [14]. - China Biopharmaceutical announced the results of a Phase III clinical study of Bemosu - bam injection at the 2025 ASCO Annual Meeting, showing significant efficacy [14]. - China Railway Group plans to issue up to RMB 3 billion in science - and - technology innovation bonds to repay debts [14]. - China National Building Material issued RMB 1.3 billion in science - and - technology innovation bonds, with different interest rates for different varieties [14]. - Tencent Holdings reduced its stake in Jingtai Holdings by over 28.42 million shares, with its shareholding dropping to 5.93% [14]. - Galectin Therapeutics' acne drug Dinifasstat's Phase III clinical trial reached all endpoints, showing significant efficacy and good safety [14]. 4. Dividend and Rights - Issue Information Dividend Information - Some companies such as Yue Yun Transportation will pay dividends, while many others, including Tsim Sha Tsui Properties, will not pay dividends [15][16]. Rights - Issue Information - Some companies like Lvji Technology have rights - issue plans [16]. 5. Stock Performance Ranking Top Gainers - Huayin International Holdings, WANMA HOLDINGS, and Dingyifeng Holdings had significant increases on June 4, 2025 [22]. US Stocks - NVIDIA, Intel, and Adobe showed different performance trends, with some rising and some falling [24]. Chinese A - Shares - Stocks such as Microcore Biotech, Feile Audio, and Shanghai Rural Commercial Bank had significant increases, while some like Kweichow Moutai had slight declines [26][27].

Market Performance - As of June 4, 2025, the Shanghai Composite Index rose by 0.42% to 3376.20 points, while the Shenzhen Component Index increased by 0.87% to 10144.58 points, and the ChiNext Index climbed by 1.11% to 2024.93 points [1] - The total trading volume of both markets reached 1.15 trillion yuan, marking the fifth consecutive day of exceeding one trillion yuan [1] - The jewelry sector showed strong performance with a daily increase of 5.95%, followed by leisure food and personal care products, which rose by 4.45% and 3.37% respectively [1] ETF Performance - A total of 1049 non-currency ETFs in the market increased, with an increase ratio of 91% [1] - The Hang Seng Innovative Drug Index rose by 3.83%, with related ETFs also showing significant gains of 3.61% and 3.55% [1] - The latest share size of the Hang Seng Innovative Drug ETF (520500.SH) reached 366 million shares, closely tracking the performance of the Hang Seng Innovative Drug Index [3] Valuation Metrics - The latest P/E ratio (PE-TTM) for the Hang Seng Innovative Drug Index is 26.92, which is lower than the average of over 11.03% in the past three years [4] - The P/E ratio for the Hang Seng Hong Kong Stock Connect Innovative Drug Index stands at 26.64, also below the average of over 12.16% in the last three years [5] - The National Certificate Hong Kong Stock Connect Innovative Drug Index has a P/E ratio of 29.36, lower than the average of over 10.84% in the past three years [5] Declining ETFs - A total of 71 non-currency ETFs declined, with a decrease ratio of 6% [5] - The top declining ETFs included the Greater Bay Area ETF, which fell by 1.41%, and the Transportation ETF, which decreased by 0.82% [7] Premium Rates - The S&P 500 Consumer Select Index showed a premium of 24.67%, while the S&P 500 Index had a premium of 17.11% [8] - The top ETFs by premium rate included the S&P Consumer ETF (24.67%) and the S&P 500 ETF (17.11%) [10]

其他蓝筹股方面，石药集团(01093)涨4.14%，报8.05港元，贡献恒指4.38点；中国生物制药(01177)涨 3.13%，报4.62港元，贡献恒指2.42点；携程集团-S(09961)跌3.94%，报485.6港元，拖累恒指5.65点；中 国联通(00762)跌2.16%，报9.07港元，拖累恒指2.08点。 热门板块方面 智通财经APP获悉，港股今日继续走高，午后涨幅曾有所扩大，国指及恒科指均一度涨超1%。截止收 盘，恒生指数涨0.6%或141.54点，报23654.03点，全日成交额为2126.87亿港元；恒生国企指数涨 0.67%，报8576.75点；恒生科技指数涨0.57%，报5219.02点。 浙商国际指出，港股市场基本面和资金面短期皆有隐忧，政策面仍在加码，而情绪面则偏观望。但鉴于 当下港股市场周月线级别趋势已进入右侧区间，对于后续走势不建议过度悲观，该行对于中短期市场走 势继续保持谨慎乐观的态度。 蓝筹股表现 美团-W(03690)表现亮眼。截至收盘，涨3%，报140.7港元，成交额85.04亿港元，贡献恒指36.9点。美 团闪购日前发布618首周战报，5月28日至6月1日，新客大幅增长 ...

Group 1 - The market experienced a rebound on June 4, with the ChiNext Index leading the gains. The total trading volume in the Shanghai and Shenzhen markets reached 1.15 trillion yuan, an increase of 11.6 billion yuan compared to the previous trading day [1] - The innovative drug concept remained active, with the Tianhong Innovative Drug ETF (517380) closing up 2.34%, reaching a peak price of 0.660 yuan, the highest since November 2023, and achieving a trading volume of nearly 20 million yuan, a two-year high [1] - The Tianhong Innovative Drug ETF (517380) has seen a year-to-date increase of 25.96% as of June 4, ranking first among all industry ETFs in the market [1] Group 2 - Changjiang Securities indicated that the valuation level of domestic innovative drugs is low, and some products have the potential to be the best in their class globally, supporting the outlook for innovative drugs to expand internationally and achieve premium valuations [2] - Guojin Securities emphasized that innovative drugs and certain semi-innovative drugs are key investment focuses, with upcoming policy changes and data releases expected to catalyze stock price movements [2] - Huafu Securities reported that the total transaction amount for innovative drug BD from 2020 to 2024 increased from 9.2 billion USD to 52.3 billion USD, with the upfront payment amount rising from 600 million USD to 4.1 billion USD [2]

Group 1 - The report indicates that the market is likely to maintain a "consolidation" phase in June, with large-cap stocks expected to see a recovery [3][12][13] - Domestic demand momentum is anticipated to improve marginally, with April industrial profits continuing a recovery trend, although both volume and price have declined [12][31] - The "barbell strategy" remains effective in the market, but there has been a notable shift towards a "concentration" phenomenon, with profit effects concentrating in the banking sector and small-cap stocks [32][33] Group 2 - The report highlights that the global supply-demand dynamics for chlorantraniliprole may be reshaped due to production capacity disruptions, with prices already entering a rebound phase [38][40] - The Chinese innovative pharmaceutical companies are gaining global influence, with significant participation in the 2025 ASCO annual meeting, showcasing advancements in drug development [38][40] - The report emphasizes the accelerating penetration of autonomous delivery vehicles, with costs approaching or even lower than human labor costs, indicating a significant shift in logistics [43][44] Group 3 - The report notes that the AI industry chain remains robust, with strong demand for computing infrastructure and significant advancements in AI applications, particularly in the context of major tech companies [46][48] - The report suggests that the market is currently in a box range, with risk appetite suppressed by fluctuating global trade policies and concerns over U.S. Treasury yields [48] - The report identifies key sectors to watch, including innovative pharmaceuticals, autonomous driving, and stablecoins, which are expected to have strong catalysts for growth [48]

Group 1 - HSBC raised the target price for China Biologic Products (01177.HK) by 34%, from HKD 3.8 to HKD 5.1, while maintaining a "Buy" rating [1] - The company is expected to see adjusted net profit forecasts increased by 39% and 45% for 2025 and 2026, respectively, due to encouraging data presented at the 2025 ASCO conference [1] - The outlook for the company's ability to achieve double-digit profit growth from 2025 to 2027 is optimistic, driven by faster-than-expected sales growth of PD-L1 and G-CSF, new drug launches, and improved operational efficiency [1] Group 2 - The company's stock price has increased by 36% year-to-date, reflecting positive market sentiment [1] - The industry is undergoing multiple commercial developments, contributing to improved sentiment within the sector [1] - The current valuation of the company is considered attractive given the industry's positive outlook [1]

该基金核心持仓包括创新药企业恒瑞医药、百济神州、信达生物、科伦药业、中国生物制药、翰森制药 以及CXO的药明康德、凯莱英和泰格医药，是少数同时布局A股和港股创新药龙头的基金，也是跟踪该 指数的全市场独家产品。 未来以创新药为核心的医药科技股有望成为行情的焦点！当前医药行业估值处于过去10年中较低水平， 其刚需属性决定行业未来兼具成长性和确定性。布局创新药，可上支付宝搜索天弘恒生沪深港创新药50 指数（C类份额：014565，A类份额：014564）。如想布局ETF的投资者，创新药ETF天弘（代码： 517380）。市场有风险，投资需谨慎，所提及个股仅作展示，不作任何推荐。 天弘恒生沪深港创新药精选50指数布局较为完整的创新药产业链，覆盖临床前研究﹣临床研究﹣研发定 制生产﹣药品上市及商业化各环节，从机制上可进一步降低投资创新药企业本身存在的不确定性，获得 较好的收益风险特征和长期投资回报。 6月4日早盘，创新药再度走强。截至11:22，恒生沪深港创新药精选50指数涨超2.7%，成股份信达生物 涨13%，泰格医药、亚盛医药﹣B、科伦药业涨超3%。 消息面上，当地时间2025年5月30日至6月3日，2025年美国 ...

Core Viewpoint - The A-share market showed overall strength on June 4, with the rare earth permanent magnet concept leading the gains [1][5][6]. A-share Market Performance - The A-share market experienced a significant rise, with the Shanghai Composite Index up by 0.43%, the Shenzhen Component Index up by 0.91%, and the ChiNext Index up by 1.22% at midday [5]. - Nearly 4,000 stocks in the market saw an increase [5]. - Key sectors such as comprehensive, communication, non-ferrous metals, and social services all recorded gains exceeding 1% [6]. Rare Earth Permanent Magnet Sector - The rare earth permanent magnet sector was notably strong, with companies like Keheng Co. hitting the daily limit with a 20.02% increase, and Jiuling Technology seeing a peak increase of over 11% [6][7]. - Other companies in this sector, such as Guangsheng Nonferrous and Zhongke Magnetic, also experienced significant gains [6]. Hong Kong Market Performance - The Hong Kong market also showed strength, with the Hang Seng Index constituents like CSPC Pharmaceutical Group and China Biologic Products leading with gains exceeding 5% [2][14]. - China General Nuclear Power Corporation saw a dramatic rise, with its stock price increasing by over 30% during trading [3][15]. Market Volatility and Stock Movements - Several stocks in the A-share market experienced consecutive trading halts, indicating high volatility [9]. - Companies like Gongchuang Turf and Zhongheng Design reported significant price fluctuations, with Gongchuang Turf's stock price deviating by 20% over two consecutive trading days [10][11]. International Context - Concerns were raised regarding China's rare earth exports potentially causing shortages in the automotive industry in Europe, the U.S., and India, prompting questions about possible export policy adjustments [8].

Group 1 - The Hong Kong stock market saw a broad increase in early trading, with the healthcare sector performing actively, particularly the Hang Seng Healthcare Index ETF (159557) which rose by 3.56% with a turnover rate of 8.1% [1] - Among the constituent stocks, Innovent Biologics surged over 17%, while Zai Lab and China National Pharmaceutical Group both increased by more than 8% [1] - The 2025 American Society of Clinical Oncology (ASCO) annual meeting is highlighted as a significant event, showcasing the latest research from local companies such as Diagreat Pharmaceuticals, Kelun Pharmaceutical, and China National Pharmaceutical Group, with over 70 original research presentations from Chinese researchers [1] Group 2 - Donghai Securities noted that the recent presentation of numerous domestic innovative drug projects at the ASCO meeting indicates the growing international recognition of local innovative pharmaceutical companies, suggesting that innovative drugs are a key investment theme within the healthcare sector [1] - The report emphasizes investment opportunities in sub-sectors such as medical devices, traditional Chinese medicine, chain pharmacies, and medical services [1] - Changjiang Securities pointed out that domestic innovative drugs are currently undervalued, with some products showing potential to be the best in their class globally, supporting the outlook for these drugs to gain international market presence and valuation upside [2]

Group 1 - The core viewpoint of the articles highlights the active performance of innovative drug ETFs, particularly Tianhong (517380), which has seen significant gains and is leading the market in terms of growth [1][2] - As of June 3, 2025, the Tianhong innovative drug ETF has accumulated a year-to-date increase of 23.08%, ranking first among all industry ETFs [1] - The Tianhong ETF tracks the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three regions, indicating a high concentration of innovation [1] Group 2 - In the first five months of 2025, the National Medical Products Administration approved over 20 first-class innovative drugs, setting a record for the same period in the past five years [2] - The recent acceleration in the approval of innovative drugs in China reflects a shift from "follow-up innovation" to "global leadership" in the pharmaceutical sector [2] - The innovative drug sector is expected to experience a valuation reshaping, with significant catalysts such as overseas business development and the ASCO conference driving interest in the sector [2]